Aligos Therapeutics said it received a $25 million upfront payment from Xiamen Amoytop Biotech under an exclusive Greater China license for peivifoscorvir sodium. The cash milestone is a positive near-term catalyst for funding and validates regional commercial/partnering progress, though there’s no update on later development or revenue beyond the upfront.
Aligos Therapeutics said it received a $25 million upfront payment from Xiamen Amoytop Biotech under an exclusive Greater China license for peivifoscorvir sodium. The cash milestone is a positive near-term catalyst for funding and validates regional commercial/partnering progress, though there’s no update on later development or revenue beyond the upfront.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
